The activist investor said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose its acquisition of Celgene.
Activist investor Starboard Value said Thursday that it intends to use its stake in Bristol-Myers Squibb to oppose the drug-maker's acquisition of Celgene.
Smith argued that Starboard was"surprised" to hear of the proposed acquisition on the heels of what he characterized as poor financial and stock price performance over the last few years.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Consulte Mais informação »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Consulte Mais informação »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Consulte Mais informação »
Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition
Consulte Mais informação »
Top Bristol-Myers shareholder comes out against $74 billion Celgene dealBristol-Myers Squibb Co's top shareholder Wellington Management said on Wed...
Consulte Mais informação »
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardyBristol-Myers Squibb Co.'s $74 billion takeover of Celgene is in jeopardy after the former's second-largest shareholder has turned against it.
Consulte Mais informação »
Value investor Greenblatt says market in expensive range historically, likes Home Depot, Boeing
Consulte Mais informação »